“Operating Expenses Research and Development Three Months Ended April 30, 2026 2025 $ Change % Change (dollars in thousands) Research and development $ 114,341 $ 81,815 $ 32,526 40 % Research and development expenses increased for the three months ended April 30, 2026 primarily due to an increase of $19.9 million in employee related costs driven by an increase in headcount, of which $13.2 million is an increase in stock-based compensation expense.”
“Other Non-Operating Income (Expense) Three Months Ended April 30, 2026 2025 $ Change % Change (dollars in thousands) Interest income $ 15,898 $ 7,696 $ 8,202 107 % Interest expense (1,070) (9,813) 8,743 (89) % Other income (expense), net 590 (5,622) 6,212 (110) % Interest income increased for the three months ended April 30, 2026 due to higher cash, cash equivalents, and investment balances.”
“The Company considers credit related impairments to be changes in value that are driven by a change in the creditor’s ability to meet its payment obligations, and it records an allowance and recognizes a corresponding loss in other income (expense), net when the impairment is incurred.”